Role of Diltiazem in Combination with Glimepiride in Diabetic Nephropathy in Experimental-induced NIDDM Model

Diabetic nephropathy (DN) is a major cause of end-stage renal disease in the general population. It estimated that DN will eventually develop about 40% all patients with diabetes; therefore, prevention critical for delaying development and progression diabetic kidney disease. Despite extensive efforts, medical advances are still not successful enough to prevent In present study, we focused on comparison combination therapies whether they offered additional renoprotection. Type 2 diabetes mellitus was induced by intraperitoneally administering streptozotocin (STZ) (90 mg/kg) neonatal rats, then, these rats were treated diltiazem (15.0 glimepiride (0.5 or pioglitazone (2.5 mg/kg). markers evaluated biochemical ELISA kits structural changes examined light microscopy transmission electron microscopy. Results show more effective amelioration than drug therapy due glycemic control, suppressing albumin excretion rate, total protein augmented tumor necrosis factor-a signaling during STZ-induced type DN.